News of Note—Trevena CMO exit; AMO deal; Kala IPO; AliveCor-Mayo pact

Thursday's news from across biopharma

> Small cap Trevena sent out a long press release this morning but waited until the end to report that its chief medical officer, David Soergel, M.D., is “planning to depart from the company in late August to pursue a new opportunity.” The hunt is on for a new CMO, the biotech said, but its shares were down premarket by 4% on the update. Statement

> AMO Pharma has penned a new license deal with private U.K. biopharma Numedicus to work on a glutamate modulator, AMO-04, as well as related compounds, for the treatment of Rett syndrome and certain breathing disorders. Financial terms were not disclosed. Release

> MIT professor Bob Langer’s Kala Pharmaceuticals has hit a $90 million IPO on the Nasdaq, pricing mid-range at $15 under the ticker "KALA." The ophthalmic drug R&D shop is eyeing the cash to equip itself to file for approvals of corticosteroid nanosuspension KPI-121 in two indications. Renaissance Capital brief


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Vic Gundotra, CEO of startup AliveCor and a former executive at Google, says his company is joining forces with the Mayo Clinic to develop tools to screen for a heart rhythm condition that can cause so-called “sudden death”. CNBC story

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.